Confronto
Liraglutide vs. Setmelanotide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
204656-20-2
920014-72-8
Peso molecolare
3751 g/mol
1117.32 g/mol
Emivita
13 h
11 h
Sequenza
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGAc-Arg-Cys(1)-D-Ala-His-D-Phe-Arg-Trp-Cys(1)-NH2 (zyklisches Oktapeptid, Disulfidbrücke Cys2–Cys8)Meccanismo d'azione
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Setmelanotide
Setmelanotide is an agonist at the melanocortin-4 receptor (MC4R), a central receptor of the hypothalamic melanocortin pathway involved in the control of energy balance, satiety and body weight. In certain genetic defects (e.g. in POMC, PCSK1 or LEPR), the natural activation of MC4R is reduced. Setmelanotide activates MC4R directly, thereby bypassing the upstream defect. This description is mechanistic and neutral and does not constitute a recommendation for use.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
4
di cui sull'uomo
4
3
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
1
3
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Liraglutide and Setmelanotide?
- Liraglutide is classified as "Metabolico", while Setmelanotide is classified as "Metabolico". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Setmelanotide: Setmelanotide (brand name Imcivree) is a synthetic cyclic octapeptide and an agonist at the melanocortin-4 receptor (MC4R). It was developed and approved as a prescription medicine for chronic weight management in rare genetic forms of obesity within the MC4R signalling pathway (including POMC, PCSK1 and LEPR deficiency as well as Bardet-Biedl syndrome). The following information is provided for informational and educational purposes only. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Liraglutide or Setmelanotide?
- The highest available evidence level is "RCT sull'uomo" for Liraglutide and "RCT sull'uomo" for Setmelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Liraglutide and Setmelanotide in Germany and the United States?
- Germania: Liraglutide — Su prescrizione, Setmelanotide — Su prescrizione. Stati Uniti: Liraglutide — Su prescrizione, Setmelanotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.